de Jong PE - Search Results

1

Enalapril and the kidney: renal vasodilation and natriuresis due to the inhibition of angiotensin II formation.

Navis GJ, de Zeeuw D, de Jong PE. Navis GJ, et al. Among authors: de jong pe, de zeeuw d. J Cardiovasc Pharmacol. 1986;8 Suppl 1:S30-4. J Cardiovasc Pharmacol. 1986. PMID: 2422491

2

The antiproteinuric effects of blood pressure-lowering agents: differences between nondiabetics and diabetics.

de Jong PE, Heeg JE, Apperloo AJ, de Zeeuw D. de Jong PE, et al. Among authors: de zeeuw d. J Cardiovasc Pharmacol. 1992;19 Suppl 6:S28-32. doi: 10.1097/00005344-199219006-00006. J Cardiovasc Pharmacol. 1992. PMID: 1382162 Review.

3

Angiotensin II does not acutely reverse the reduction of proteinuria by long-term ACE inhibition.

Heeg JE, de Jong PE, van der Hem GK, de Zeeuw D. Heeg JE, et al. Among authors: de jong pe, de zeeuw d. Kidney Int. 1991 Oct;40(4):734-41. doi: 10.1038/ki.1991.268. Kidney Int. 1991. PMID: 1660550 Free article. Clinical Trial.

4

Differential effects of enalapril and atenolol on proteinuria and renal haemodynamics in non-diabetic renal disease.

Apperloo AJ, de Zeeuw D, Sluiter HE, de Jong PE. Apperloo AJ, et al. Among authors: de jong pe, de zeeuw d. BMJ. 1991 Oct 5;303(6806):821-4. doi: 10.1136/bmj.303.6806.821. BMJ. 1991. PMID: 1932973 Free PMC article. Clinical Trial.

5

Lisinopril in hypertensive patients with renal function impairment.

de Jong PE, Apperloo AJ, Heeg JE, de Zeeuw D. de Jong PE, et al. Among authors: de zeeuw d. Nephron. 1990;55 Suppl 1:43-8. doi: 10.1159/000186034. Nephron. 1990. PMID: 2161083

6

Renal effects of ketanserin in essential hypertension.

Navis G, de Jong PE, van der Hem GK, de Zeeuw D. Navis G, et al. Among authors: de jong pe, de zeeuw d. J Hypertens Suppl. 1986 Apr;4(1):S95-8. J Hypertens Suppl. 1986. PMID: 2939222

7

Atrial natriuretic factor influences renal diurnal rhythm in essential hypertension.

Janssen WM, de Zeeuw D, van der Hem GK, de Jong PE. Janssen WM, et al. Among authors: de jong pe, de zeeuw d. Hypertension. 1992 Jul;20(1):80-4. doi: 10.1161/01.hyp.20.1.80. Hypertension. 1992. PMID: 1535613

8

Additive antiproteinuric effect of angiotensin-converting enzyme inhibition and non-steroidal anti-inflammatory drug therapy: a clue to the mechanism of action.

Heeg JE, de Jong PE, de Zeeuw D. Heeg JE, et al. Among authors: de jong pe, de zeeuw d. Clin Sci (Lond). 1991 Sep;81(3):367-72. doi: 10.1042/cs0810367. Clin Sci (Lond). 1991. PMID: 1655338 Clinical Trial.

9

Angiotensin-I converting enzyme inhibition: clinical effects in chronic renal disease.

de Jong PE, Heeg JE, Apperloo AJ, de Zeeuw D. de Jong PE, et al. Among authors: de zeeuw d. Am J Kidney Dis. 1991 May;17(5 Suppl 1):85-8. Am J Kidney Dis. 1991. PMID: 2024682 Review. No abstract available.

10

Additive antiproteinuric effect of the NSAID indomethacin and the ACE inhibitor lisinopril.

Heeg JE, de Jong PE, Vriesendorp R, de Zeeuw D. Heeg JE, et al. Among authors: de jong pe, de zeeuw d. Am J Nephrol. 1990;10 Suppl 1:94-7. doi: 10.1159/000168201. Am J Nephrol. 1990. PMID: 2175149 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

454 results

Search Page

Filters